ArticleChemistry & biodiversity2025
Lupeol-Loaded Liposomes: Triple-Negative Breast Cancer (TNBC) Cytotoxicity and In Vivo Toxicological Evaluation.
Article in Chemistry & biodiversity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Dietary Terpenoids in Advancing Biofilm-Mediated Cancer Prevention: Antibiofilm Cascade, Molecular Crosstalk, and Nano-Facilitated Functional Delivery.Cell biochemistry and function · 2026Review
- Lupeol-Loaded Liposomes: Triple-Negative Breast Cancer (TNBC) Cytotoxicity and In Vivo Toxicological Evaluation.Chemistry & biodiversity · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lupeol is a natural product commonly found in many vegetables and fruits in significant quantities. Previous studies have demonstrated the relevant activity of lupeol against various tumor cell lines, suggesting that the natural product could be a promising agent for cancer treatment. Due to bioavailability requirements, lupeol presents a challenge for internal administration in therapeutic doses. Thus, the development of pharmaceutical formulations, particularly nanostructured systems, could represent an important alternative to improving the bioavailability of the molecule. This study developed and characterized a liposomal formulation loaded with lupeol, exhibiting substantial cytotoxic, cytostatic, and apoptotic profiles against the MDA-MB-231 tumor cells, a triple-negative human breast cancer subtype. Toxicological in vivo evaluations revealed a nonrelevant toxic profile against healthy mice. Considering all the results obtained, the present study revealed important potentialities of the liposomal system, constituting a potential therapeutic alternative against triple-negative breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.